nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—CYP1A2—Carmustine—lymphatic system cancer	0.0641	1	CbGbCtD
Betaxolol—Respiratory failure—Methotrexate—lymphatic system cancer	0.00177	0.00189	CcSEcCtD
Betaxolol—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.00177	0.00189	CcSEcCtD
Betaxolol—Eye disorder—Carmustine—lymphatic system cancer	0.00176	0.00188	CcSEcCtD
Betaxolol—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00176	0.00188	CcSEcCtD
Betaxolol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00175	0.00187	CcSEcCtD
Betaxolol—Flushing—Carmustine—lymphatic system cancer	0.00175	0.00187	CcSEcCtD
Betaxolol—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00174	0.00186	CcSEcCtD
Betaxolol—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00174	0.00186	CcSEcCtD
Betaxolol—Anaemia—Bleomycin—lymphatic system cancer	0.00174	0.00186	CcSEcCtD
Betaxolol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00172	0.00184	CcSEcCtD
Betaxolol—Asthenia—Teniposide—lymphatic system cancer	0.00171	0.00182	CcSEcCtD
Betaxolol—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.0017	0.00181	CcSEcCtD
Betaxolol—Malaise—Bleomycin—lymphatic system cancer	0.00169	0.00181	CcSEcCtD
Betaxolol—Pruritus—Teniposide—lymphatic system cancer	0.00168	0.0018	CcSEcCtD
Betaxolol—Arrhythmia—Carmustine—lymphatic system cancer	0.00168	0.0018	CcSEcCtD
Betaxolol—Cystitis—Methotrexate—lymphatic system cancer	0.00168	0.00179	CcSEcCtD
Betaxolol—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00168	0.00179	CcSEcCtD
Betaxolol—Cardiac disorder—Vincristine—lymphatic system cancer	0.00167	0.00178	CcSEcCtD
Betaxolol—Alopecia—Carmustine—lymphatic system cancer	0.00167	0.00178	CcSEcCtD
Betaxolol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00165	0.00177	CcSEcCtD
Betaxolol—Mental disorder—Carmustine—lymphatic system cancer	0.00165	0.00176	CcSEcCtD
Betaxolol—Erythema—Carmustine—lymphatic system cancer	0.00164	0.00175	CcSEcCtD
Betaxolol—Malnutrition—Carmustine—lymphatic system cancer	0.00164	0.00175	CcSEcCtD
Betaxolol—Cough—Bleomycin—lymphatic system cancer	0.00164	0.00175	CcSEcCtD
Betaxolol—Angiopathy—Vincristine—lymphatic system cancer	0.00163	0.00174	CcSEcCtD
Betaxolol—Diarrhoea—Teniposide—lymphatic system cancer	0.00163	0.00174	CcSEcCtD
Betaxolol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00162	0.00173	CcSEcCtD
Betaxolol—Chest pain—Bleomycin—lymphatic system cancer	0.0016	0.00171	CcSEcCtD
Betaxolol—Myalgia—Bleomycin—lymphatic system cancer	0.0016	0.00171	CcSEcCtD
Betaxolol—Alopecia—Vincristine—lymphatic system cancer	0.00159	0.0017	CcSEcCtD
Betaxolol—Discomfort—Bleomycin—lymphatic system cancer	0.00158	0.00169	CcSEcCtD
Betaxolol—Mental disorder—Vincristine—lymphatic system cancer	0.00158	0.00168	CcSEcCtD
Betaxolol—Chills—Mitoxantrone—lymphatic system cancer	0.00157	0.00168	CcSEcCtD
Betaxolol—Bladder pain—Methotrexate—lymphatic system cancer	0.00157	0.00168	CcSEcCtD
Betaxolol—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00157	0.00168	CcSEcCtD
Betaxolol—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00157	0.00167	CcSEcCtD
Betaxolol—Alopecia—Mitoxantrone—lymphatic system cancer	0.00155	0.00165	CcSEcCtD
Betaxolol—Confusional state—Bleomycin—lymphatic system cancer	0.00155	0.00165	CcSEcCtD
Betaxolol—Vision blurred—Carmustine—lymphatic system cancer	0.00155	0.00165	CcSEcCtD
Betaxolol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00154	0.00165	CcSEcCtD
Betaxolol—Tremor—Carmustine—lymphatic system cancer	0.00154	0.00164	CcSEcCtD
Betaxolol—Oedema—Bleomycin—lymphatic system cancer	0.00153	0.00164	CcSEcCtD
Betaxolol—Erythema—Mitoxantrone—lymphatic system cancer	0.00153	0.00163	CcSEcCtD
Betaxolol—Infection—Bleomycin—lymphatic system cancer	0.00152	0.00163	CcSEcCtD
Betaxolol—Anaemia—Carmustine—lymphatic system cancer	0.00152	0.00162	CcSEcCtD
Betaxolol—Vomiting—Teniposide—lymphatic system cancer	0.00151	0.00162	CcSEcCtD
Betaxolol—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.0015	0.0016	CcSEcCtD
Betaxolol—Asthenia—Fludarabine—lymphatic system cancer	0.0015	0.0016	CcSEcCtD
Betaxolol—Rash—Teniposide—lymphatic system cancer	0.0015	0.0016	CcSEcCtD
Betaxolol—Dermatitis—Teniposide—lymphatic system cancer	0.0015	0.0016	CcSEcCtD
Betaxolol—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00149	0.0016	CcSEcCtD
Betaxolol—Headache—Teniposide—lymphatic system cancer	0.00149	0.00159	CcSEcCtD
Betaxolol—Pruritus—Fludarabine—lymphatic system cancer	0.00148	0.00158	CcSEcCtD
Betaxolol—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00148	0.00158	CcSEcCtD
Betaxolol—Anorexia—Bleomycin—lymphatic system cancer	0.00146	0.00156	CcSEcCtD
Betaxolol—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00146	0.00156	CcSEcCtD
Betaxolol—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00145	0.00155	CcSEcCtD
Betaxolol—Anaemia—Vincristine—lymphatic system cancer	0.00145	0.00155	CcSEcCtD
Betaxolol—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00144	0.00154	CcSEcCtD
Betaxolol—Hypotension—Bleomycin—lymphatic system cancer	0.00143	0.00153	CcSEcCtD
Betaxolol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00143	0.00153	CcSEcCtD
Betaxolol—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00141	0.00151	CcSEcCtD
Betaxolol—Nausea—Teniposide—lymphatic system cancer	0.00141	0.00151	CcSEcCtD
Betaxolol—Anaemia—Mitoxantrone—lymphatic system cancer	0.00141	0.00151	CcSEcCtD
Betaxolol—Vertigo—Vincristine—lymphatic system cancer	0.00141	0.0015	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.0014	0.00149	CcSEcCtD
Betaxolol—Chest pain—Carmustine—lymphatic system cancer	0.0014	0.00149	CcSEcCtD
Betaxolol—Myalgia—Carmustine—lymphatic system cancer	0.0014	0.00149	CcSEcCtD
Betaxolol—Anxiety—Carmustine—lymphatic system cancer	0.00139	0.00149	CcSEcCtD
Betaxolol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00138	0.00147	CcSEcCtD
Betaxolol—Malaise—Mitoxantrone—lymphatic system cancer	0.00138	0.00147	CcSEcCtD
Betaxolol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00137	0.00146	CcSEcCtD
Betaxolol—Confusional state—Carmustine—lymphatic system cancer	0.00135	0.00144	CcSEcCtD
Betaxolol—Oedema—Carmustine—lymphatic system cancer	0.00134	0.00143	CcSEcCtD
Betaxolol—Decreased appetite—Bleomycin—lymphatic system cancer	0.00133	0.00142	CcSEcCtD
Betaxolol—Myalgia—Vincristine—lymphatic system cancer	0.00133	0.00142	CcSEcCtD
Betaxolol—Cough—Mitoxantrone—lymphatic system cancer	0.00133	0.00142	CcSEcCtD
Betaxolol—Infection—Carmustine—lymphatic system cancer	0.00133	0.00142	CcSEcCtD
Betaxolol—Vomiting—Fludarabine—lymphatic system cancer	0.00133	0.00142	CcSEcCtD
Betaxolol—Rash—Fludarabine—lymphatic system cancer	0.00132	0.00141	CcSEcCtD
Betaxolol—Dermatitis—Fludarabine—lymphatic system cancer	0.00132	0.00141	CcSEcCtD
Betaxolol—Pain—Bleomycin—lymphatic system cancer	0.00131	0.0014	CcSEcCtD
Betaxolol—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00131	0.0014	CcSEcCtD
Betaxolol—Headache—Fludarabine—lymphatic system cancer	0.00131	0.0014	CcSEcCtD
Betaxolol—Tachycardia—Carmustine—lymphatic system cancer	0.00131	0.0014	CcSEcCtD
Betaxolol—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0013	0.00139	CcSEcCtD
Betaxolol—Chest pain—Mitoxantrone—lymphatic system cancer	0.0013	0.00139	CcSEcCtD
Betaxolol—Myalgia—Mitoxantrone—lymphatic system cancer	0.0013	0.00139	CcSEcCtD
Betaxolol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00129	0.00138	CcSEcCtD
Betaxolol—Lethargy—Methotrexate—lymphatic system cancer	0.00129	0.00138	CcSEcCtD
Betaxolol—Discomfort—Mitoxantrone—lymphatic system cancer	0.00128	0.00137	CcSEcCtD
Betaxolol—Oedema—Vincristine—lymphatic system cancer	0.00128	0.00137	CcSEcCtD
Betaxolol—Anorexia—Carmustine—lymphatic system cancer	0.00128	0.00136	CcSEcCtD
Betaxolol—Infection—Vincristine—lymphatic system cancer	0.00127	0.00136	CcSEcCtD
Betaxolol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00126	0.00135	CcSEcCtD
Betaxolol—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00126	0.00135	CcSEcCtD
Betaxolol—Confusional state—Mitoxantrone—lymphatic system cancer	0.00125	0.00134	CcSEcCtD
Betaxolol—Nervous system disorder—Vincristine—lymphatic system cancer	0.00125	0.00134	CcSEcCtD
Betaxolol—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00125	0.00134	CcSEcCtD
Betaxolol—Hypotension—Carmustine—lymphatic system cancer	0.00125	0.00134	CcSEcCtD
Betaxolol—Oedema—Mitoxantrone—lymphatic system cancer	0.00124	0.00133	CcSEcCtD
Betaxolol—Nausea—Fludarabine—lymphatic system cancer	0.00124	0.00133	CcSEcCtD
Betaxolol—Infection—Mitoxantrone—lymphatic system cancer	0.00124	0.00132	CcSEcCtD
Betaxolol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00124	0.00132	CcSEcCtD
Betaxolol—Shock—Mitoxantrone—lymphatic system cancer	0.00122	0.00131	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Betaxolol—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Betaxolol—Urticaria—Bleomycin—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Betaxolol—Anorexia—Vincristine—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Betaxolol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00121	0.0013	CcSEcCtD
Betaxolol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00121	0.0013	CcSEcCtD
Betaxolol—Insomnia—Carmustine—lymphatic system cancer	0.00121	0.00129	CcSEcCtD
Betaxolol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00121	0.00129	CcSEcCtD
Betaxolol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0012	0.00129	CcSEcCtD
Betaxolol—Paraesthesia—Carmustine—lymphatic system cancer	0.0012	0.00128	CcSEcCtD
Betaxolol—Mood swings—Methotrexate—lymphatic system cancer	0.0012	0.00128	CcSEcCtD
Betaxolol—Hypotension—Vincristine—lymphatic system cancer	0.00119	0.00128	CcSEcCtD
Betaxolol—Dyspnoea—Carmustine—lymphatic system cancer	0.00119	0.00128	CcSEcCtD
Betaxolol—Anorexia—Mitoxantrone—lymphatic system cancer	0.00119	0.00127	CcSEcCtD
Betaxolol—Ataxia—Methotrexate—lymphatic system cancer	0.00119	0.00127	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
Betaxolol—Decreased appetite—Carmustine—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
Betaxolol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
Betaxolol—Insomnia—Vincristine—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00116	0.00124	CcSEcCtD
Betaxolol—Paraesthesia—Vincristine—lymphatic system cancer	0.00115	0.00123	CcSEcCtD
Betaxolol—Pain—Carmustine—lymphatic system cancer	0.00114	0.00122	CcSEcCtD
Betaxolol—Constipation—Carmustine—lymphatic system cancer	0.00114	0.00122	CcSEcCtD
Betaxolol—Breast disorder—Methotrexate—lymphatic system cancer	0.00114	0.00122	CcSEcCtD
Betaxolol—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00114	0.00121	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00113	0.00121	CcSEcCtD
Betaxolol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00113	0.00121	CcSEcCtD
Betaxolol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00112	0.00119	CcSEcCtD
Betaxolol—Decreased appetite—Vincristine—lymphatic system cancer	0.00111	0.00119	CcSEcCtD
Betaxolol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00111	0.00119	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.0011	0.00118	CcSEcCtD
Betaxolol—Feeling abnormal—Carmustine—lymphatic system cancer	0.0011	0.00118	CcSEcCtD
Betaxolol—Fatigue—Vincristine—lymphatic system cancer	0.0011	0.00118	CcSEcCtD
Betaxolol—Asthenia—Bleomycin—lymphatic system cancer	0.0011	0.00118	CcSEcCtD
Betaxolol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0011	0.00117	CcSEcCtD
Betaxolol—Pain—Vincristine—lymphatic system cancer	0.00109	0.00117	CcSEcCtD
Betaxolol—Constipation—Vincristine—lymphatic system cancer	0.00109	0.00117	CcSEcCtD
Betaxolol—Asthma—Methotrexate—lymphatic system cancer	0.00109	0.00117	CcSEcCtD
Betaxolol—Pruritus—Bleomycin—lymphatic system cancer	0.00109	0.00116	CcSEcCtD
Betaxolol—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00108	0.00116	CcSEcCtD
Betaxolol—Fatigue—Mitoxantrone—lymphatic system cancer	0.00107	0.00115	CcSEcCtD
Betaxolol—Pain—Mitoxantrone—lymphatic system cancer	0.00106	0.00114	CcSEcCtD
Betaxolol—Constipation—Mitoxantrone—lymphatic system cancer	0.00106	0.00114	CcSEcCtD
Betaxolol—Body temperature increased—Carmustine—lymphatic system cancer	0.00106	0.00113	CcSEcCtD
Betaxolol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00103	0.0011	CcSEcCtD
Betaxolol—Dysuria—Methotrexate—lymphatic system cancer	0.00102	0.00109	CcSEcCtD
Betaxolol—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00101	0.00108	CcSEcCtD
Betaxolol—Body temperature increased—Vincristine—lymphatic system cancer	0.00101	0.00108	CcSEcCtD
Betaxolol—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.001	0.00107	CcSEcCtD
Betaxolol—Urticaria—Mitoxantrone—lymphatic system cancer	0.000989	0.00106	CcSEcCtD
Betaxolol—Hypersensitivity—Carmustine—lymphatic system cancer	0.000986	0.00105	CcSEcCtD
Betaxolol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000984	0.00105	CcSEcCtD
Betaxolol—Pneumonia—Methotrexate—lymphatic system cancer	0.000978	0.00104	CcSEcCtD
Betaxolol—Vomiting—Bleomycin—lymphatic system cancer	0.000975	0.00104	CcSEcCtD
Betaxolol—Infestation NOS—Methotrexate—lymphatic system cancer	0.000972	0.00104	CcSEcCtD
Betaxolol—Infestation—Methotrexate—lymphatic system cancer	0.000972	0.00104	CcSEcCtD
Betaxolol—Depression—Methotrexate—lymphatic system cancer	0.00097	0.00104	CcSEcCtD
Betaxolol—Rash—Bleomycin—lymphatic system cancer	0.000967	0.00103	CcSEcCtD
Betaxolol—Dermatitis—Bleomycin—lymphatic system cancer	0.000966	0.00103	CcSEcCtD
Betaxolol—Asthenia—Carmustine—lymphatic system cancer	0.000961	0.00103	CcSEcCtD
Betaxolol—Stomatitis—Methotrexate—lymphatic system cancer	0.000948	0.00101	CcSEcCtD
Betaxolol—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000945	0.00101	CcSEcCtD
Betaxolol—Hypersensitivity—Vincristine—lymphatic system cancer	0.000942	0.00101	CcSEcCtD
Betaxolol—Sweating—Methotrexate—lymphatic system cancer	0.000932	0.000996	CcSEcCtD
Betaxolol—Epistaxis—Methotrexate—lymphatic system cancer	0.000917	0.00098	CcSEcCtD
Betaxolol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000917	0.00098	CcSEcCtD
Betaxolol—Asthenia—Vincristine—lymphatic system cancer	0.000917	0.00098	CcSEcCtD
Betaxolol—Diarrhoea—Carmustine—lymphatic system cancer	0.000916	0.000979	CcSEcCtD
Betaxolol—Nausea—Bleomycin—lymphatic system cancer	0.000911	0.000973	CcSEcCtD
Betaxolol—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000907	0.00097	CcSEcCtD
Betaxolol—Asthenia—Mitoxantrone—lymphatic system cancer	0.000893	0.000954	CcSEcCtD
Betaxolol—Dizziness—Carmustine—lymphatic system cancer	0.000885	0.000946	CcSEcCtD
Betaxolol—Diarrhoea—Vincristine—lymphatic system cancer	0.000874	0.000934	CcSEcCtD
Betaxolol—Pharyngitis—Methotrexate—lymphatic system cancer	0.000866	0.000926	CcSEcCtD
Betaxolol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000852	0.00091	CcSEcCtD
Betaxolol—Vomiting—Carmustine—lymphatic system cancer	0.000851	0.00091	CcSEcCtD
Betaxolol—Dizziness—Vincristine—lymphatic system cancer	0.000845	0.000903	CcSEcCtD
Betaxolol—Rash—Carmustine—lymphatic system cancer	0.000844	0.000902	CcSEcCtD
Betaxolol—Dermatitis—Carmustine—lymphatic system cancer	0.000843	0.000901	CcSEcCtD
Betaxolol—Visual impairment—Methotrexate—lymphatic system cancer	0.000841	0.000899	CcSEcCtD
Betaxolol—Headache—Carmustine—lymphatic system cancer	0.000839	0.000896	CcSEcCtD
Betaxolol—Eye disorder—Methotrexate—lymphatic system cancer	0.000816	0.000872	CcSEcCtD
Betaxolol—Tinnitus—Methotrexate—lymphatic system cancer	0.000814	0.00087	CcSEcCtD
Betaxolol—Vomiting—Vincristine—lymphatic system cancer	0.000813	0.000868	CcSEcCtD
Betaxolol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00081	0.000866	CcSEcCtD
Betaxolol—Rash—Vincristine—lymphatic system cancer	0.000806	0.000861	CcSEcCtD
Betaxolol—Dermatitis—Vincristine—lymphatic system cancer	0.000805	0.00086	CcSEcCtD
Betaxolol—Headache—Vincristine—lymphatic system cancer	0.000801	0.000856	CcSEcCtD
Betaxolol—Nausea—Carmustine—lymphatic system cancer	0.000795	0.00085	CcSEcCtD
Betaxolol—Angiopathy—Methotrexate—lymphatic system cancer	0.000792	0.000846	CcSEcCtD
Betaxolol—Vomiting—Mitoxantrone—lymphatic system cancer	0.000791	0.000846	CcSEcCtD
Betaxolol—Immune system disorder—Methotrexate—lymphatic system cancer	0.000788	0.000842	CcSEcCtD
Betaxolol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000787	0.000841	CcSEcCtD
Betaxolol—Rash—Mitoxantrone—lymphatic system cancer	0.000785	0.000839	CcSEcCtD
Betaxolol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000784	0.000838	CcSEcCtD
Betaxolol—Chills—Methotrexate—lymphatic system cancer	0.000783	0.000837	CcSEcCtD
Betaxolol—Headache—Mitoxantrone—lymphatic system cancer	0.00078	0.000833	CcSEcCtD
Betaxolol—Alopecia—Methotrexate—lymphatic system cancer	0.000771	0.000824	CcSEcCtD
Betaxolol—Mental disorder—Methotrexate—lymphatic system cancer	0.000765	0.000817	CcSEcCtD
Betaxolol—Malnutrition—Methotrexate—lymphatic system cancer	0.00076	0.000812	CcSEcCtD
Betaxolol—Erythema—Methotrexate—lymphatic system cancer	0.00076	0.000812	CcSEcCtD
Betaxolol—Nausea—Vincristine—lymphatic system cancer	0.000759	0.000811	CcSEcCtD
Betaxolol—Dysgeusia—Methotrexate—lymphatic system cancer	0.000744	0.000795	CcSEcCtD
Betaxolol—Nausea—Mitoxantrone—lymphatic system cancer	0.000739	0.00079	CcSEcCtD
Betaxolol—Vision blurred—Methotrexate—lymphatic system cancer	0.000716	0.000765	CcSEcCtD
Betaxolol—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000705	0.000753	CcSEcCtD
Betaxolol—Anaemia—Methotrexate—lymphatic system cancer	0.000702	0.00075	CcSEcCtD
Betaxolol—Malaise—Methotrexate—lymphatic system cancer	0.000685	0.000732	CcSEcCtD
Betaxolol—Vertigo—Methotrexate—lymphatic system cancer	0.000683	0.000729	CcSEcCtD
Betaxolol—Cough—Methotrexate—lymphatic system cancer	0.000663	0.000708	CcSEcCtD
Betaxolol—Arthralgia—Methotrexate—lymphatic system cancer	0.000647	0.000691	CcSEcCtD
Betaxolol—Myalgia—Methotrexate—lymphatic system cancer	0.000647	0.000691	CcSEcCtD
Betaxolol—Chest pain—Methotrexate—lymphatic system cancer	0.000647	0.000691	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000642	0.000686	CcSEcCtD
Betaxolol—Discomfort—Methotrexate—lymphatic system cancer	0.000639	0.000683	CcSEcCtD
Betaxolol—Confusional state—Methotrexate—lymphatic system cancer	0.000625	0.000668	CcSEcCtD
Betaxolol—Infection—Methotrexate—lymphatic system cancer	0.000616	0.000658	CcSEcCtD
Betaxolol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000608	0.00065	CcSEcCtD
Betaxolol—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000607	0.000649	CcSEcCtD
Betaxolol—Skin disorder—Methotrexate—lymphatic system cancer	0.000602	0.000644	CcSEcCtD
Betaxolol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000599	0.000641	CcSEcCtD
Betaxolol—Anorexia—Methotrexate—lymphatic system cancer	0.000591	0.000632	CcSEcCtD
Betaxolol—Hypotension—Methotrexate—lymphatic system cancer	0.000579	0.000619	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000565	0.000604	CcSEcCtD
Betaxolol—Insomnia—Methotrexate—lymphatic system cancer	0.000561	0.000599	CcSEcCtD
Betaxolol—Paraesthesia—Methotrexate—lymphatic system cancer	0.000557	0.000595	CcSEcCtD
Betaxolol—Dyspnoea—Methotrexate—lymphatic system cancer	0.000553	0.000591	CcSEcCtD
Betaxolol—Dyspepsia—Methotrexate—lymphatic system cancer	0.000546	0.000583	CcSEcCtD
Betaxolol—Decreased appetite—Methotrexate—lymphatic system cancer	0.000539	0.000576	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000535	0.000572	CcSEcCtD
Betaxolol—Fatigue—Methotrexate—lymphatic system cancer	0.000535	0.000571	CcSEcCtD
Betaxolol—Pain—Methotrexate—lymphatic system cancer	0.00053	0.000567	CcSEcCtD
Betaxolol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000511	0.000546	CcSEcCtD
Betaxolol—Urticaria—Methotrexate—lymphatic system cancer	0.000493	0.000526	CcSEcCtD
Betaxolol—Body temperature increased—Methotrexate—lymphatic system cancer	0.00049	0.000524	CcSEcCtD
Betaxolol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000457	0.000488	CcSEcCtD
Betaxolol—Asthenia—Methotrexate—lymphatic system cancer	0.000445	0.000475	CcSEcCtD
Betaxolol—Pruritus—Methotrexate—lymphatic system cancer	0.000439	0.000469	CcSEcCtD
Betaxolol—Diarrhoea—Methotrexate—lymphatic system cancer	0.000424	0.000453	CcSEcCtD
Betaxolol—Dizziness—Methotrexate—lymphatic system cancer	0.00041	0.000438	CcSEcCtD
Betaxolol—Vomiting—Methotrexate—lymphatic system cancer	0.000394	0.000421	CcSEcCtD
Betaxolol—Rash—Methotrexate—lymphatic system cancer	0.000391	0.000418	CcSEcCtD
Betaxolol—Dermatitis—Methotrexate—lymphatic system cancer	0.000391	0.000417	CcSEcCtD
Betaxolol—Headache—Methotrexate—lymphatic system cancer	0.000388	0.000415	CcSEcCtD
Betaxolol—Nausea—Methotrexate—lymphatic system cancer	0.000368	0.000394	CcSEcCtD
